Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Natera Inc
(NQ:
NTRA
)
105.51
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Natera Inc
< Previous
1
2
3
4
5
6
Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
March 08, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth...
Via
Benzinga
Natera: Q4 Earnings Insights
February 24, 2022
Natera (NASDAQ:NTRA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Natera...
Via
Benzinga
Natera's Debt Overview
February 22, 2022
Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has. Check...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Analyzing Natera's Unusual Options Activity
August 04, 2021
On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual o...
Via
Benzinga
What Does Natera's Debt Look Like?
August 03, 2021
Over the past three months, shares of Natera (NASDAQ:NTRA) moved higher by 10.31%. Before we understand the importance of debt, let us look at how much debt Natera has....
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results
January 17, 2022
--News Direct--
Via
News Direct
7 Stocks to Buy in November in Light of Their October Dip
November 15, 2021
October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick.
Via
InvestorPlace
Expert Ratings For Natera
July 20, 2021
Within the last quarter, Natera (NASDAQ:NTRA) has observe...
Via
Benzinga
Analyst Ratings For Natera
June 22, 2021
Within the last quarter, Natera (NASDAQ:NTRA) has observed...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring
November 11, 2021
CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
January 07, 2022
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap...
Via
Benzinga
Natera Raises FY21 Sales Outlook After Mixed Q3 earnings
November 05, 2021
Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product...
Via
Benzinga
Natera Inc (NTRA) Q3 2021 Earnings Call Transcript
November 05, 2021
NTRA earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
CEO And President Of Natera Trades $2.4M In Company Stock
October 06, 2021
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Notable Natera Insider Trades $3M In Company Stock
September 30, 2021
Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
CEO And President Of Natera Trades $3.41 Million In Company Stock
September 27, 2021
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Return on Capital Employed Overview: Natera
August 30, 2021
After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a...
Via
Benzinga
Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook
August 06, 2021
Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus...
Via
Benzinga
3 Stocks Insiders Are Buying
July 27, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
July 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,...
Via
Benzinga
Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings
July 19, 2021
Natera Inc (NASDAQ: NTRA) expects 2Q'21 revenues of approximately $138 million to $141 million, equivalent to around 60% Y/Y growth. The Company's revenue...
Via
Benzinga
This Explosive Biotech Is Taking On a Huge New Market
June 30, 2021
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Via
The Motley Fool
10 Biggest Price Target Changes For Monday
June 21, 2021
SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.